Physician profile
Amy L Olson
NPI 1265409056
$117,299.68
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $43K · 2021: $4,535 · 2022: $3,091.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63,552.37 | 2019-2021 | |
| Genentech USA, INC. | $27,251.51 | 2019-2020 | |
| Boehringer Ingelheim International Gmbh | $12,459.67 | 2019-2022 | |
| Medical Graphics Corporation | $11,840.22 | 2019-2020 | |
| Genentech, INC. | $2,000.00 | 2020 | |
| United Therapeutics Corporation | $111.29 | 2020 | |
| Beckman Coulter, INC. | $40.90 | 2019 | |
| Glaxosmithkline, LLC. | $26.14 | 2019-2020 | |
| Advanced Respiratory, INC | $17.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.